首页> 外文期刊>Drug development and industrial pharmacy >7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: Optimized formulation, characterization and in-vivo evaluation
【24h】

7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: Optimized formulation, characterization and in-vivo evaluation

机译:一种新型制备方法的7-乙基-10-羟基喜树碱前脂质体:优化的制剂,表征和体内评价

获取原文
获取原文并翻译 | 示例
           

摘要

Context: The proliposomes were used to solve the stability of the ordinary liposomes. Objective: 7-ethyl-10-hydroxycamptothecin (SN-38) proliposomes for intravenous (i.v.) administration were prepared successfully by a new method. Materials and methods:SN-38 liposomes solution was reconstituting automatically from proliposomes on contact with the acetic acid buffer solution (0.2 M, pH 2.6). The formulation was optimized by the Box-Behnken design. The physicochemical characteristics of the SN-38 proliposomes were studied by scanning electron microscopy (SEM), transmission electron microscopy (TEM), differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The stability studies were also carried on. The FLU-HPLC system was served to study the concentration of SN-38 in the plasma of Sprague Dawley (SD) rats. Results:The optimized formulation was SN-38: 0.03 g; Soybean phospholipid (SP): 0.6 g; dextrose: 3.00 g. The entrapment efficiency of the optimized formulation was >85% and the mean particle size was about 231 nm. The stability studies showed that SN-38 proliposomes were stable in dark at 20-25??C for 6 months at least. The pharmacokinetic parameters of i.v. administration demonstrated that the half-life of SN-38 loaded in the liposomes was prolonged in vivo. Discussion and conclusion:The SN-38 proliposomes was prepared successful by the analysis of TEM, SEM, DSC and XRD, and SN-38 liposomes could be reconstituted on contact with the hydration medium. SN-38 liposomes circulated for a longer time in the blood circulating system than SN-38 solution, which contributed to maintaining the drug action. ? 2013 Informa Healthcare USA, Inc.
机译:背景:前脂质体用于解决普通脂质体的稳定性。目的:通过一种新方法成功制备了静脉内(i.v.)给药的7-乙基-10-羟基喜树碱(SN-38)脂质体。材料与方法:SN-38脂质体溶液在与乙酸缓冲液(0.2 M,pH 2.6)接触后由脂质体自动重构。通过Box-Behnken设计优化了配方。通过扫描电子显微镜(SEM),透射电子显微镜(TEM),差示扫描量热法(DSC)和X射线衍射(XRD)研究了SN-38脂质体的理化特性。还进行了稳定性研究。 FLU-HPLC系统用于研究Sprague Dawley(SD)大鼠血浆中SN-38的浓度。结果:优化配方为SN-38:0.03 g;大豆磷脂(SP):0.6 g;葡萄糖:3.00克。优化配方的包封率> 85%,平均粒径约为231 nm。稳定性研究表明,SN-38脂质体在黑暗中于20-25°C至少可稳定6个月。 i.v.的药代动力学参数施用证明在脂质体内负载的SN-38的半衰期延长。讨论与结论:通过TEM,SEM,DSC和XRD分析,成功制备了SN-38脂质体,与水合介质接触后可重构SN-38脂质体。 SN-38脂质体在血液循环系统中的循环时间比SN-38溶液更长,这有助于维持药物作用。 ? 2013年Informa Healthcare USA,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号